The United States Food and Drug Administration (FDA) has announced tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories and Aurobindo Pharma Limited, both based in India. These are the first generic versions of nevirapine tablets to be approved for purchase by the President's Emergency Plan for AIDS Relief (PEPFAR).

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs) used in combination with other antiretroviral agents for the treatment of HIV-1 infection.

The use of single dose nevirapine for the prevention of mother to child transmission of HIV is permitted under PEPFAR.

The FDA's tentative approval means that although existing patents and/or exclusivity prevent the marketing of Aurobindo's and Ranbaxy's products in the United States, these products meet all of the agency's quality, safety and efficacy standards required for marketing in the United States. Therefore, they are eligible to be considered for purchase and use outside the United States under the PEPFAR program.

aidsmap resources

latest news

• Up to half of gay men diagnosed with HIV in UK may have been infected in previous year
• UK conference discusses the `Swiss statement` on infectiousness of people on HIV treatment
• Treating co-infections can lower HIV viral load, reducing risk of transmission and improving prognosis
• Unsuccessful post-exposure prophylaxis may still result in weaker HIV infection and lower viral load
• Jury still out on whether circumcision protects gay men against HIV
• Nobel prize awarded to French discoverers of HIV
• Resistance to darunavir related to pre-existing mutations
• Fall in number of undiagnosed HIV infections in the US
• Antiretroviral therapy does not fully reverse impact of HIV on hepatitis C-related cirrhosis
• High early mortality after starting antiretroviral treatment in Africa